Pharmalucence, Inc. Announces FDA Approval for Use of Sulfur Colloid Injection to Locate Lymph Nodes in Breast Cancer Patients

Published: Jul 25, 2011

BEDFORD, Mass.--(BUSINESS WIRE)--Pharmalucence, Inc. (www.pharmalucence.com) has received FDA approval expanding the route of administration and use of its Sulfur Colloid Injection (SCI) to include location of lymph nodes in breast cancer patients.

Back to news